AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-246525341/biosante-pharmaceuticals-closes-18.html" title="Facts and information about BioSante Pharmaceuticals closes $18 M registered direct offering to fund LibiGel for female sexual dysfunction.">BioSante Pharmaceuticals closes $18 M registered direct offering to fund LibiGel for female sexual dysfunction.</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
BioSante Pharmaceuticals closes $18 M registered direct offering to fund LibiGel for female sexual dysfunction.
On 31 Dec 2010 BioSante Pharmaceuticals Inc announced the closing of a previously announced sale of an aggregate of $18 M of securities in a registered direct offering. BioSante received net proceeds of approximately $16.9 M after deducting placement agent fees and other offering expenses. BioSante sold an aggregate of approximately 10.6 M shares of its …
Related articles from newspapers, magazines, journals, and more
-
- BioSante Pharmaceuticals announces $7.6 M private placement of common stock.
-
News wire article from: Chemical Business Newsbase
July 10, 2006
700+ words
-
- BioSante Pharmaceuticals announces $17.7 M private placement of common stock.
-
News wire article from: Asia Africa Intelligence Wire
May 12, 2004
700+ words
-
- BioSante Pharmaceuticals completes $17.7 M private placement of common stock.
-
News wire article from: Asia Africa Intelligence Wire
May 14, 2004
700+ words
-
- BioSante Pharmaceuticals and Cell Genesys announce final exchange ratio for...
-
News wire article from: Chemical Business Newsbase
September 22, 2009
700+ words
-
- BioSante Pharmaceuticals Inc plans oneforsix reverse stock split.
-
News wire article from: Europe Intelligence Wire
June 5, 2012
700+ words
